JP2011513437A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513437A5
JP2011513437A5 JP2010550000A JP2010550000A JP2011513437A5 JP 2011513437 A5 JP2011513437 A5 JP 2011513437A5 JP 2010550000 A JP2010550000 A JP 2010550000A JP 2010550000 A JP2010550000 A JP 2010550000A JP 2011513437 A5 JP2011513437 A5 JP 2011513437A5
Authority
JP
Japan
Prior art keywords
moiety
cancerous cells
compound
prooxidant
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010550000A
Other languages
English (en)
Japanese (ja)
Other versions
JP5616798B2 (ja
JP2011513437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/000312 external-priority patent/WO2009111846A1/en
Publication of JP2011513437A publication Critical patent/JP2011513437A/ja
Publication of JP2011513437A5 publication Critical patent/JP2011513437A5/ja
Application granted granted Critical
Publication of JP5616798B2 publication Critical patent/JP5616798B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010550000A 2008-03-14 2009-03-16 ミトコンドリア由来の抗ガン化合物 Expired - Fee Related JP5616798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008901261A AU2008901261A0 (en) 2008-03-14 Mitochondrially Delivered Anti-Cancer Compounds
AU2008901261 2008-03-14
PCT/AU2009/000312 WO2009111846A1 (en) 2008-03-14 2009-03-16 Mitochondrially delivered anti-cancer compounds

Publications (3)

Publication Number Publication Date
JP2011513437A JP2011513437A (ja) 2011-04-28
JP2011513437A5 true JP2011513437A5 (enExample) 2013-05-02
JP5616798B2 JP5616798B2 (ja) 2014-10-29

Family

ID=41064682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550000A Expired - Fee Related JP5616798B2 (ja) 2008-03-14 2009-03-16 ミトコンドリア由来の抗ガン化合物

Country Status (7)

Country Link
US (2) USRE47300E1 (enExample)
EP (1) EP2265623B1 (enExample)
JP (1) JP5616798B2 (enExample)
KR (1) KR101642157B1 (enExample)
CA (1) CA2734208C (enExample)
NZ (1) NZ602579A (enExample)
WO (1) WO2009111846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6163479B2 (ja) 2011-04-14 2017-07-12 エクサレンズ バイオサイエンス リミテッド 肝細胞癌の診断、予後診断、監視および治療方法
US10012653B2 (en) 2011-06-15 2018-07-03 Board Of Regents, The University Of Texas System Nanoparticles for targeting acid tumor microenvironments
HK1200459A1 (en) 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
US9220706B2 (en) 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
WO2014173374A1 (en) * 2013-04-24 2014-10-30 Smart Brain s.r.o. Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
WO2016144637A1 (en) * 2015-03-06 2016-09-15 The Children's Hospital Of Philadelphia Tocopheryloxyacetate ester-based co-drug conjugates
CZ307146B6 (cs) * 2015-03-31 2018-02-07 Kkcg Se Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva
EP3370737B1 (en) 2015-11-04 2021-09-22 Prescient Pharma LLC Anti-aging compositions and methods for using same
KR102361131B1 (ko) * 2020-02-25 2022-02-10 경희대학교 산학협력단 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물
US20230372529A1 (en) * 2020-10-22 2023-11-23 Paean Biotechnology Inc. Mitochondria comprising anticancer drug and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
RU2263672C2 (ru) 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
AUPQ605800A0 (en) * 2000-03-06 2000-03-30 Silverbrook Research Pty Ltd Printehead assembly
EP1387978A1 (en) * 2001-05-17 2004-02-11 Imperial College Innovations Limited Production and processing plant with a rigid pipe portion curving in three dimensions
AU2004266988B2 (en) 2003-08-22 2011-05-26 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
CA2575216A1 (en) 2004-07-28 2006-02-09 Sd Pharmaceuticals, Inc. Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof
KR100556527B1 (ko) * 2004-11-04 2006-03-06 삼성전자주식회사 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법
WO2006094203A1 (en) 2005-03-02 2006-09-08 Northeastern University Mitochondriotropic phospholipid vesicles
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
CA2663474C (en) 2006-09-15 2017-06-27 Griffith University Pro-oxidant anti-cancer compounds
JP4930026B2 (ja) * 2006-12-13 2012-05-09 富士ゼロックス株式会社 積層体、無端状ベルト、定着装置及び画像形成装置
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung

Similar Documents

Publication Publication Date Title
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
JP2016517434A5 (enExample)
JP2010525050A5 (enExample)
WO2009111846A4 (en) Mitochondrially delivered anti-cancer compounds
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
NZ595767A (en) Composition for the treatment of prostate cancer
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
NO20080244L (no) Doseringsstyring for prasugrel
MX2013003523A (es) Composicion farmaceutica de dosis baja.
JP2016505050A5 (enExample)
CN104337916A (zh) 一种手脚冰凉及脚气的中药药剂
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
ES2950096T3 (es) Método para aliviar los síntomas del síndrome premenstrual
CN101439160A (zh) 玉米提取物防治肿瘤的用途
CN101933963A (zh) 一种治疗头痛的鼻用原位凝胶剂
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
CN102319260A (zh) 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
CN102631421A (zh) 一种治疗老年痴呆病的中药
CN105497003B (zh) 淫羊藿苷元在制备预防或治疗肺纤维化药物中的应用
CN101856359A (zh) 一种抗急性髓系白血病的药物组合物
TW201444561A (zh) 可治療癌症之藥學組合物
CN103371987B (zh) 漆酚化合物在制备抑制肾脏组织纤维化的药物中的用途
CN101904860B (zh) 盐酸环维黄杨星d与灯盏花素组合物
CN100584854C (zh) 圆锥绣球有效部位、其制备方法及其组合物与用途